Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Capsules Relative to That From Co-administration of ABT-335 and Rosuvastatin for the 5/45mg Dosage Form.

AstraZeneca32 enrolled

Overview

The purpose of this study is to compare the pharmacokinetics of ABT-335 and rosuvastatin from ABT-143 relative to that from the co-administration of ABT-335 and rosuvastatin.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Adverse Events Pharmacokinetic Variables

Interventions

ABT-143DRUG

once

ABT-335 and rosuvastatinDRUG

once

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Signed informed consent * Condition of good health Exclusion Criteria: * Currently enrolled in another study * Females who are pregnant or breast feeding

Locations (1)

Site Reference ID/Investigator# 11101

Evansville, Indiana, United States

Outcomes

Primary Outcomes

Adverse events and safety laboratory assessments

Time frame: 7 days

Pharmacokinetic parameters

Time frame: 7 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.